The FDA's March 2024 approval of TMS for adolescent depression (ages 15-21) gives clinicians a powerful new tool in our therapeutic arsenal.
With only two FDA-approved medications for this age group and rising post-pandemic depression rates, this clearance couldn't come at a more critical time.
With only two FDA-approved medications for this age group and rising post-pandemic depression rates, this clearance couldn't come at a more critical time.
Comments
-Real-world efficacy data from 10,000+ adolescent cases showing PHQ-9 reductions comparable to adults
-Practical protocols that fit your practice workflow
-Insurance authorization strategies (including recent wins with Aetna)
-Documentation essentials for clean reimbursement
-Tips for parent education that drive engagement
Whether you're looking to expand your existing TMS practice or starting fresh with adolescent cases, this session equips you with actionable protocols and pearls.
https://osmind.org/blog/tms-adolescent-depression…